Your browser is no longer supported. Please, upgrade your browser.
BYSI BeyondSpring Inc. monthly Stock Chart
BYSI [NASD]
BeyondSpring Inc.
Index- P/E- EPS (ttm)-2.04 Insider Own86.85% Shs Outstand30.30M Perf Week8.54%
Market Cap334.36M Forward P/E- EPS next Y-2.72 Insider Trans0.00% Shs Float3.61M Perf Month-23.30%
Income-57.50M PEG- EPS next Q-0.49 Inst Own7.10% Short Float23.07% Perf Quarter-8.20%
Sales- P/S- EPS this Y36.20% Inst Trans-10.62% Short Ratio3.19 Perf Half Y-31.27%
Book/sh0.79 P/B14.16 EPS next Y-33.30% ROA-140.00% Target Price- Perf Year-13.99%
Cash/sh1.03 P/C10.82 EPS next 5Y- ROE-220.70% 52W Range9.38 - 21.50 Perf YTD-27.81%
Dividend- P/FCF- EPS past 5Y-48.10% ROI- 52W High-47.95% Beta0.57
Dividend %- Quick Ratio2.80 Sales past 5Y- Gross Margin- 52W Low19.30% ATR1.10
Employees61 Current Ratio2.80 Sales Q/Q- Oper. Margin- RSI (14)36.94 Volatility6.11% 8.52%
OptionableNo Debt/Eq0.09 EPS Q/Q-29.60% Profit Margin- Rel Volume2.64 Prev Close10.89
ShortableYes LT Debt/Eq0.09 EarningsSep 03 BMO Payout- Avg Volume261.00K Price11.19
Recom1.30 SMA20-19.86% SMA50-21.22% SMA200-21.12% Volume688,870 Change2.75%
Feb-07-20Initiated Jefferies Buy $25
Jan-10-20Initiated Nomura Buy $34
Dec-03-19Initiated William Blair Outperform
Jul-10-19Reiterated H.C. Wainwright Buy $60 → $41
Apr-30-19Downgrade Maxim Group Buy → Hold
Oct-25-18Reiterated Maxim Group Buy $48 → $35
Nov-24-20 08:59PM  
Nov-23-20 04:01PM  
Nov-19-20 08:00AM  
Nov-17-20 04:01PM  
08:00AM  
Nov-16-20 07:00AM  
Nov-13-20 04:46PM  
07:00AM  
Oct-14-20 07:00AM  
Oct-12-20 07:00AM  
Sep-29-20 08:00AM  
Sep-24-20 08:00AM  
Sep-22-20 08:30AM  
07:43AM  
Sep-11-20 08:00AM  
Sep-10-20 08:37AM  
Sep-08-20 07:00AM  
Sep-03-20 03:30PM  
07:00AM  
Aug-27-20 08:00AM  
Aug-18-20 08:00AM  
Aug-11-20 08:00AM  
Jun-30-20 07:00AM  
Jun-24-20 12:02AM  
Jun-23-20 08:00AM  
Jun-19-20 05:32AM  
Jun-18-20 04:06PM  
Jun-15-20 07:00AM  
Jun-11-20 08:00AM  
Jun-09-20 08:00AM  
Jun-03-20 08:00AM  
Jun-02-20 08:00AM  
May-13-20 08:00AM  
May-01-20 08:00AM  
Apr-30-20 05:05PM  
07:00AM  
Apr-29-20 08:00AM  
Apr-23-20 08:00AM  
Mar-30-20 08:00AM  
Mar-26-20 11:06AM  
Mar-23-20 09:00AM  
Mar-11-20 08:00AM  
Feb-10-20 08:00AM  
Jan-23-20 08:00AM  
Jan-06-20 08:00AM  
Dec-19-19 08:00AM  
Dec-18-19 07:00AM  
Dec-11-19 09:01AM  
Dec-10-19 08:02AM  
Dec-09-19 08:01AM  
Nov-11-19 08:00AM  
Nov-06-19 08:05AM  
Oct-25-19 09:01AM  
Oct-24-19 04:03PM  
Oct-23-19 08:00AM  
Oct-17-19 08:00AM  
Oct-08-19 08:00AM  
Oct-01-19 08:00AM  
Sep-26-19 12:39PM  
Sep-23-19 08:00AM  
Sep-18-19 07:00AM  
06:00AM  
Sep-11-19 08:00AM  
Sep-10-19 08:00AM  
Sep-06-19 07:00AM  
Aug-23-19 08:00AM  
Jul-17-19 09:05AM  
Jul-16-19 04:07PM  
Jul-10-19 08:23AM  
Jun-28-19 02:19PM  
Jun-20-19 08:00AM  
Jun-04-19 08:00AM  
May-20-19 08:03AM  
May-16-19 08:01AM  
Apr-30-19 04:15PM  
11:23AM  
07:30AM  
06:00AM  
Apr-24-19 04:30PM  
Apr-04-19 04:30PM  
Mar-26-19 07:30AM  
Mar-25-19 07:30AM  
Mar-20-19 07:30AM  
Mar-05-19 07:30AM  
Feb-26-19 07:30AM  
Jan-17-19 05:14AM  
Dec-27-18 07:30AM  
Dec-21-18 07:30AM  
Dec-06-18 07:30AM  
Dec-04-18 12:35PM  
Nov-30-18 06:23AM  
Nov-27-18 07:00AM  
Nov-21-18 07:45AM  
Nov-08-18 07:30AM  
Oct-23-18 07:00AM  
07:00AM  
07:00AM  
Oct-19-18 07:00AM  
Oct-16-18 07:06AM  
Oct-05-18 01:19PM  
BeyondSpring Inc., a clinical stage biopharmaceutical company, together with its subsidiaries, focuses on the development and commercialization of immuno-oncology cancer therapies. The company's lead asset is the Plinabulin that is in late stage clinical trials as an anti-cancer agent in combination with docetaxel in advanced non-small cell lung cancer (NSCLC) for the prevention of high and intermediate risk chemotherapy-induced neutropenia. It is also developing Plinabulin in combination with various immuno-oncology agents, including nivolumab, a programmed cell death protein 1 antibody for the treatment of NSCLC; nivolumab and ipilimumab, a CTLA-4 antibody to treat small cell lung cancer; and death protein 1 or programmed death-ligand 1, an antibodies and radiation or chemotherapy for the treatment of multiple cancers. In addition, the company engages in the development of three small molecule immune agents in preclinical stages; and a drug development platform using ubiquitin mediated protein degradation pathway. BeyondSpring Inc. has collaboration agreements with the Fred Hutchinson Cancer Research Center and the University of Washington. The company was founded in 2010 and is headquartered in New York, New York.
affiliate | advertise | contact | privacy | help
Do not sell my personal information

Quotes delayed 15 minutes for NASDAQ, and 20 minutes for NYSE and AMEX.
Copyright © 2007-2020 FINVIZ.com. All Rights Reserved.